TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04586348

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Low Iodine Supplement
Description: Multivitamin and mineral supplement with reduced iodine

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Standard Iodine Supplement
Description: Multivitamin and mineral supplement with standard amount of iodine to match current leading brands of prenatal supplements
Study: NCT06410261

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise rehabilitation program
Description: * The sessions will consist of a customized low-impact, resistance-base rehabilitation regime to increase muscle strength and functionality by focusing on isolating each targeted muscle, without increasing the participant's fatigue or pain level.~* The goal of phase one will be to start muscle activation without increasing fatigue or pain. Low intensity, single set of 30-35 repetitions for each of the targeted muscles will be performed by the participants, followed by stretching; the goal of phase two will be to progressively develop muscle strength, without increasing pain or fatigue. A single set of 20-25 repetitions for each muscle will be prescribed, followed by stretching; during phase three, the emphasis will be on further development of muscle strength, function, and endurance.
Study: NCT05083013

Intervention type: DIAGNOSTIC_TEST
Intervention: Reverse transcription polymerase chain reaction (RT-PCR)
Description: For SARS Corona Virus 2 (COV2) confirmation

Intervention type: DIAGNOSTIC_TEST
Intervention: Reverse transcription polymerase chain reaction (RT-PCR)
Description: For SARS Corona Virus 2 (COV2) confirmation

Intervention type: DIAGNOSTIC_TEST
Intervention: Glycated haemoglobin (HbA1C)
Description: Diabetic patients' group will be categorized according to their glycemic control by using their glycated haemoglobin (HBA1C) into good control, fair control and poor control

Intervention type: DIAGNOSTIC_TEST
Intervention: Glycated haemoglobin (HbA1C)
Description: Diabetic patients' group will be categorized according to their glycemic control by using their glycated haemoglobin (HBA1C) into good control, fair control and poor control

Intervention type: RADIATION
Intervention: High Resolution Computed Tomography (HRCT)
Description: with the coronavirus disease 2019 Reporting and Data System (CO-RADS) classification grade 5 for SARS COV2 confirmation

Intervention type: RADIATION
Intervention: High Resolution Computed Tomography (HRCT)
Description: with the coronavirus disease 2019 Reporting and Data System (CO-RADS) classification grade 5 for SARS COV2 confirmation

Intervention type: DIAGNOSTIC_TEST
Intervention: Routine Laboratory investigations
Description: * Arterial blood gases (ABGs)~* Routine Laboratory investigations (Urea, Creatinine, Liver function tests, Serum Electrolytes, Prothrombin Concentration)

Intervention type: DIAGNOSTIC_TEST
Intervention: Routine Laboratory investigations
Description: * Arterial blood gases (ABGs)~* Routine Laboratory investigations (Urea, Creatinine, Liver function tests, Serum Electrolytes, Prothrombin Concentration)

Intervention type: DIAGNOSTIC_TEST
Intervention: Random Blood Sugar (RBS)
Description: Blood Sugar will be measured before each meal and before bed time during hospitalization.

Intervention type: DIAGNOSTIC_TEST
Intervention: Random Blood Sugar (RBS)
Description: Blood Sugar will be measured before each meal and before bed time during hospitalization.
Study: NCT05158335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBX 2109 (Part A)
Description: Single ascending SC dose of MBX 2109: 50 µg, 150 µg, 300 µg, 460 µg, 600 µg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBX 2109 (Part B)
Description: Repeated ascending SC doses of MBX 2109: 200 µg, 300 µg, 460 µg, 600 µg, 900 µg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single SC dose or repeated SC doses of placebo.
Study: NCT06010641

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: head-down position
Description: -20° Trendelenburg as an adjunct to guideline-based treatment,

Intervention type: OTHER
Group type: OTHER
Intervention: head-down position
Description: -20° Trendelenburg as an adjunct to guideline-based treatment,
Study: NCT04137588

Intervention type: DRUG
Intervention: Antiangiogenesis Agents
Description: antiangiogenesis agents plus chemotherapy as first line treatment

Intervention type: DRUG
Intervention: Antiangiogenesis Agents
Description: antiangiogenesis agents plus chemotherapy as first line treatment

Intervention type: DRUG
Intervention: Immune checkpoint inhibitor
Description: immune checkpoint inhibitor plus chemotherapy as first line treatment

Intervention type: DRUG
Intervention: Immune checkpoint inhibitor
Description: immune checkpoint inhibitor plus chemotherapy as first line treatment
Study: NCT06319469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: silodosin 8 mg capsule and the pyridostigmine bromide 60 mg tablet
Description: The participants were assigned to groups A and B. Group B received the 8 mg silodosin capsule. In contrast, Group A was administered the silodosin 8 mg capsule and the pyridostigmine bromide 60 mg tablet. Over a week, each group administered their designated drug once per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: silodosin 8 mg capsule
Description: The participants were assigned to groups A and B. Group B received the 8 mg silodosin capsule. In contrast, Group A was administered the silodosin 8 mg capsule and the pyridostigmine bromide 60 mg tablet. Over a week, each group administered their designated drug once per day
Study: NCT05201430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOXIRI
Description: irinotecan\* 165 mg/m² iv continue for 1.5 hours, D1 oxaliplatin 85 mg/m² iv continue for 2 hours, D1 leucovorin 400 mg/m² iv continue for 2 hours, D1 5-FU 2400\~3200 mg/m² cont. inf. 48h, D1 repeat every 2 weeks (Q2W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CapeOX
Description: oxaliplatin 130 mg/m2 iv continue for 2 hours, D1 capecitabine 1000mg/m2/d PO Bid, once every morning and evening D1-14 repeat every 3 weeks (Q3W)
Study: NCT05717374

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: caudal block using dexamethasone
Description: patient will receive 0.5 ml/kg volume (bupivacaine 0.25 % + dexamethasone 0.1mg/kg) through the sacral hiatus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: caudal block using methylprednisolone
Description: patients will receive 0.5 ml/kg volume (bupivacaine 0.25% + methylprednisolone 0.5mg/kg) through the sacral hiatus
Study: NCT03681392

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dr. Pyke's Supplement for Stream (S4S)
Description: Proprietary combination of Panax ginseng extract, L-citrulline, beta-sitosterol and vitamin D3

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dr. Pyke's Supplement for Stream (S4S)
Description: Proprietary combination of Panax ginseng extract, L-citrulline, beta-sitosterol and vitamin D3
Study: NCT06359067

Intervention type: OTHER
Intervention: Treated by bispecific antibodies, teclistamab or elranatamab in usual care
Description: Treated by bispecific antibodies, teclistamab or elranatamab in usual care

Intervention type: OTHER
Intervention: Not treated by bispecific antibodies in usual care
Description: Not treated by bispecific antibodies in usual care
Study: NCT06166849

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental Fluoride Application
Description: The two-step system, consisting of Component A and Component B, will be applied once on the white spot lesions
Study: NCT05091099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alendronate
Description: On time Zoledronate: Zoledronate would be given (one dose for one year) after the completiong of denosumab on time Alendronate and Zoledronate: Alendronate would be given one month before the the completiong of denosumab and the following 3 months (Total four months). After the completion of Alendronate, Zoledronate would be given (one dose).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alendronate
Description: On time Zoledronate: Zoledronate would be given (one dose for one year) after the completiong of denosumab on time Alendronate and Zoledronate: Alendronate would be given one month before the the completiong of denosumab and the following 3 months (Total four months). After the completion of Alendronate, Zoledronate would be given (one dose).
Study: NCT03764865

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: day 3 uterine transfer
Description: uterine transfer of embryo on day 3 after fertilization (cleavage stage)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: day 5 uterine transfer
Description: uterine transfer of embryo on day 5 after fertilization (blastocyst stage)
Study: NCT06135220

Intervention type: DIAGNOSTIC_TEST
Intervention: New method for diagnosis of pulmonary embolism (PE) in order to validate/consolidate 151 putative identified biomarkers for PE in the exhaled breath.
Description: The collection time will be an average of 7 minutes. As the patient breathes through a mouthpiece, the exhaled breath is lead through the collection device, and an indicative amount af the exhaled air is led into a clear plastic bag. When the plastic bag is fully inflated, it indicates that the minimum required amount of exhaled breath (approximately 30 liters) has passed through the filter.
Study: NCT05292040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3857210
Description: Administered orally.
Study: NCT05911776

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nasal packing Dexmedetomidine
Description: patients will receive nasal packing Dexmedetomidine (1.5 μg/kg intranasal dexmedetomidine diluted with saline) and Intravenous infusion saline.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Dexmedetomidine
Description: patients will receive 0.5 μg/kg bolus over 10 min then 0.1- 0.4 μg/kg Intravenous infusion Dexmedetomidine and nasal packing with saline.
Study: NCT05495841

Intervention type: DEVICE
Intervention: Pre-oxygenation
Description: Process of administrating oxygen prior to intubation

Intervention type: DEVICE
Intervention: Pre-oxygenation
Description: Process of administrating oxygen prior to intubation
Study: NCT05499455

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positional Sleep Belt
Description: Rematee Positional Sleep Belt

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Control Device
Study: NCT06584331

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 1 dose of Beetroot juice intake
Description: The volunteers will ingest 70 ml of beetroot juice with 400 mg of nitrate every morning for 10 days

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 2 doses of Beetroot juice intake
Description: This group will ingest 2 shots of 70 ml of beetroot juice with 400mg of nitrate, in each shot, for 10 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In this group, the participants will receive 70ml of low-nitrate beetroot juice to consume in the morning.
Study: NCT05692934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR20031 FDC
Description: Subjects will receive treatment HR20031 FDC 10/100/1000 mg in the fast state followed by 7 days washout ，then receive treatment HR20031 FDC 10/100/1000 mg in the fed state .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR20031 FDC
Description: Subjects will receive treatment HR20031 FDC 10/100/1000 mg in the fed state followed by 7 days washout ，then receive treatment HR20031 FDC 10/100/1000 mg in the fast state.
Study: NCT06135220

Intervention type: DIAGNOSTIC_TEST
Intervention: New method for diagnosis of pulmonary embolism (PE) in order to validate/consolidate 151 putative identified biomarkers for PE in the exhaled breath.
Description: The collection time will be an average of 7 minutes. As the patient breathes through a mouthpiece, the exhaled breath is lead through the collection device, and an indicative amount af the exhaled air is led into a clear plastic bag. When the plastic bag is fully inflated, it indicates that the minimum required amount of exhaled breath (approximately 30 liters) has passed through the filter.

Intervention type: DIAGNOSTIC_TEST
Intervention: New method for diagnosis of pulmonary embolism (PE) in order to validate/consolidate 151 putative identified biomarkers for PE in the exhaled breath.
Description: The collection time will be an average of 7 minutes. As the patient breathes through a mouthpiece, the exhaled breath is lead through the collection device, and an indicative amount af the exhaled air is led into a clear plastic bag. When the plastic bag is fully inflated, it indicates that the minimum required amount of exhaled breath (approximately 30 liters) has passed through the filter.
Study: NCT05692934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR20031 FDC
Description: Subjects will receive treatment S HR20031 FDC 5/50/750 mg\*2 in the fast state followed by 7 days washout ，then receive treatment HR20031 FDC 5/50/750 mg\*2 in the fed state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR20031 FDC
Description: Subjects will receive treatment HR20031 FDC 5/50/750 mg\*2 in the fed state followed by 7 days washout ，then receive treatment HR20031 FDC 5/50/750 mg\*2 in the fast state.
Study: NCT06324942

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surgeon-administered Transversus Abdominis Plane Block 0.25% bupivicaine 0.25 mL/kg
Description: Surgeon-administered Transversus Abdominis Plane Block
Study: NCT05553340

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education for caregivers
Description: The intervention will aim to equip the family caregiver to assist the elderly in activities of daily living after discharge, and will be carried out by two researchers, through an online course. The course includes the skills required and included in the scales that assess the caregiver's knowledge and performance. The course is divided into 12 modules that can be accessed as many times as needed by caregivers, in random order, according to the care needs of the elderly and the caregiver.
Study: NCT06331416

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telemonitoring
Description: Patients will be asked to carry out one measurement (arterial pressure, oxygen saturation, body temperature, heart rate, spirometry) every 24 hours for 90 days. The system will be supplied by the company Vivisol. The telemonitoring data will be read once a day and the principal investigator will be alerted in case of alteration of any parameter. If vital parameters remain stable, a phone call will be performed every 5 days. In case of compromise of any parameter, the patient will be offered a phone call within the same day. In case of new occurrence of any respiratory or non-respiratory symptoms, the patient must contact the principal investigator and he will be offered a phone call or a video-assisted call within the same day. If the alterations or symptoms persist for 24 hours, or in any case upon decision of the investigator in charge, the patient will be offered an in-person evaluation in the same day. If deemed necessary according to usual care, the patient will be hospitalized.
Study: NCT04542785

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rate control
Description: Treatment will be provided according to current guidelines and as such the algorithm for treatment will be differentiated based on the status of left ventricular ejection fraction. For participants with reduced left ventricular ejection fraction, beta-blockers (metoprolol and bisoprolol) will be the primary therapy. Secondary therapies may include digoxin or amiodarone. For participants with preserved left ventricular ejection fraction, the primary therapy will be beta-blockers (metoprolol and bisoprolol) or non-dihydropyridine calcium-channel blockers (verapamil) with secondary therapy consisting of digoxin or amiodarone. Pacing therapies, alone or with atrioventricular node ablation, are utilised as indicated in the view of the treating physician.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rate control
Description: Treatment will be provided according to current guidelines and as such the algorithm for treatment will be differentiated based on the status of left ventricular ejection fraction. For participants with reduced left ventricular ejection fraction, beta-blockers (metoprolol and bisoprolol) will be the primary therapy. Secondary therapies may include digoxin or amiodarone. For participants with preserved left ventricular ejection fraction, the primary therapy will be beta-blockers (metoprolol and bisoprolol) or non-dihydropyridine calcium-channel blockers (verapamil) with secondary therapy consisting of digoxin or amiodarone. Pacing therapies, alone or with atrioventricular node ablation, are utilised as indicated in the view of the treating physician.
Study: NCT06145776

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: tDCS + tredmill training (Standart trehab training)
Description: Standart Rehab training will consist in 20 min treadmill gait training associated to active atDCS F3 2mA for 20 min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tDCS + tredmill training (Standart trehab training)
Description: Standart Rehab training will consist in 20 min treadmill gait training associated to active atDCS F3 2mA for 20 min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitite-motor Dual Task Training (DT training)
Description: The dual-task training protocol (DT) will consist in cognitive exercises (verbal fluency, mental screening tasks, discrimination, decision-making and reaction time tasks) and motor exercises (walking while carrying a tray with only one empty glasscarrying a glass while walks, change peaces from one pocket to another, looking from one side to another while walking)
Study: NCT06051929

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Intervention for Emotional Distress(MIED)
Description: The MIED program integrates the rationales and practices from the Unified Protocol for Treatment of Emotional Disorders (UP) and Mindfulness based Interventions. Formal mindfulness exercises (e.g., body scan, mindful breathing, and mindful stretching) and informal mindfulness practices (e.g., mindful tooth brushing) were adapted from Mindfulness based intervention (MBIs). The offline received the 8-week (2.5-h per week) sessions.The online MIED program was delivered by a Chat Mini Program and lasted for 49 days. Each day, participants received different materials including (a) an audio recording of mindfulness meditation guidance; (b) learning materials in text or audio; and (c) assignments (for example, informal mindfulness practice, emotion journal, and challenging tasks). In total, it took about 30 min per day to finish all the tasks.
Study: NCT05641207

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RheOx™ with the RheOx™ Catheter treated in the trial
Description: Eligible patients be assigned two sessions of RheOx bronchial rheoplasty procedures~* Treatment 1 is for the treatment of right lung~* Treatment 2 is scheduled one month apart for left lung
Study: NCT05496387

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sciatic nerve neuromobilization techniques
Description: Sciatic nerve neuromobilization techniques (tension and sliding) was applied to the dominant side lower extremities of all participants in the study. While the participant was trying to bring her chin closer to her chest by flexing her head and neck, she simultaneously brought her foot to dorsiflexion. After waiting 30 seconds in this tense position, the ankle, head and neck returned to neutral position and relaxed. 3 sets were repeated with 1 minute rest breaks. Sciatic nerve sliding was applied in the same starting position as tension. While the participants was trying to bring her chin closer to her chest by flexing her head and neck, she simultaneously brought her foot to plantar flexion.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sciatic nerve neuromobilization techniques
Description: Sciatic nerve neuromobilization techniques (tension and sliding) was applied to the dominant side lower extremities of all participants in the study. While the participant was trying to bring her chin closer to her chest by flexing her head and neck, she simultaneously brought her foot to dorsiflexion. After waiting 30 seconds in this tense position, the ankle, head and neck returned to neutral position and relaxed. 3 sets were repeated with 1 minute rest breaks. Sciatic nerve sliding was applied in the same starting position as tension. While the participants was trying to bring her chin closer to her chest by flexing her head and neck, she simultaneously brought her foot to plantar flexion.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sciatic nerve neuromobilization techniques
Description: Sciatic nerve neuromobilization techniques (tension and sliding) was applied to the dominant side lower extremities of all participants in the study. While the participant was trying to bring her chin closer to her chest by flexing her head and neck, she simultaneously brought her foot to dorsiflexion. After waiting 30 seconds in this tense position, the ankle, head and neck returned to neutral position and relaxed. 3 sets were repeated with 1 minute rest breaks. Sciatic nerve sliding was applied in the same starting position as tension. While the participants was trying to bring her chin closer to her chest by flexing her head and neck, she simultaneously brought her foot to plantar flexion.
Study: NCT05412238

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: micro-and macro-nutrients fortified sachets
Description: Every subject receives daily fortified sachets containing micro-and macronutrients for 6-9 months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: micro-and macro-nutrients fortified sachets
Description: Every subject receives daily fortified sachets containing micro-and macronutrients for 6-9 months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: micro-and macro-nutrients fortified sachets
Description: Every subject receives daily fortified sachets containing micro-and macronutrients for 6-9 months
Study: NCT04513288

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental treatment L-citrulline (Protéocit®)
Description: Enteral administration of citrulline for 5 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo treatment
Description: Enteral administration of iso-nitrogenous placebo for 5 days.
Study: NCT05842044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: 15-30mg Ketorolac administered via injection during intraoperative period every six (6) hours during post-surgery (inpatient) period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: 1000mg Acetaminophen administered orally during preoperative period. Standardized regimen of Acetaminophen administered during post-surgery (inpatient) period, during postoperative follow-up period.
Study: NCT04761679

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Applying the Mepilex foam
Description: Mepilex foam will be directly applied on the nasal bridge directly between the skin and the N95 mask.